V&E Advises on $7.3B Biogen Acquisition of Reata Pharmaceuticals
Plano-based Reata specializes in the treatment of neurological complications with cellular metabolism and inflammation associated with neurological diseases. The all-cash transaction is being treated as a combination and is expected to close in the fourth quarter of this year.